Company / Operating Cash Flow per Share
Kymera Therapeutics, Inc. Operating Cash Flow per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.59
FY2025
5-year range
-$3.59 / $0.40
FY2021-FY2025
Trend
-2.6%
vs FY2024
Sector context
#178 of 212
Health Care
What the data says
Kymera Therapeutics, Inc.'s operating cash flow per share of $-3.59 is lower than 84% of companies in the Health Care sector (FY2025). Declined from $-2.14 to $-3.59 over the past 2 years.
Based on SEC 10-K filings.
-3.59 in FY2025.
Declined from $-2.14 to $-3.59 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 212This company -$3.59 Sector average $5.28
▼
-168.0% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 2.6% year-over-year.
- Ranks #178 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.59 | -2.6% |
| FY2024 | -$3.50 | -63.3% |
| FY2023 | -$2.14 | +27.9% |
| FY2022 | -$2.97 | -838.0% |
| FY2021 | $0.40 | -95.7% |
| FY2020 | $9.28 | -12.0% |
| FY2019 | $10.54 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026